[go: up one dir, main page]

UY32304A - Composición de liberación pulsátil de sildenafil y proceso para prepararla - Google Patents

Composición de liberación pulsátil de sildenafil y proceso para prepararla

Info

Publication number
UY32304A
UY32304A UY0001032304A UY32304A UY32304A UY 32304 A UY32304 A UY 32304A UY 0001032304 A UY0001032304 A UY 0001032304A UY 32304 A UY32304 A UY 32304A UY 32304 A UY32304 A UY 32304A
Authority
UY
Uruguay
Prior art keywords
sildenafil
pulsatable
prepare
release
release composition
Prior art date
Application number
UY0001032304A
Other languages
English (en)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32304(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of UY32304A publication Critical patent/UY32304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de sildenafil de liberación pulsátil que comprende una fracción de liberación inmediata que contiene 5 a 100 mg de sildenafil y una fracción de liberación controlada que contiene 25 a 150 mg de sildenafil, en donde la fracción de liberación controlada está compuesto por partículas que contienen (a) un agente superdesintegrante, (b) un recubrimiento formado por al menos un polímero de solubilidad pH-dependiente y al menos un polímero de solubilidad pH-independiente y (c) opcionalmente otros excipientes farmacéuticas. La composición de la presente invención presenta un perfil de disolución más rápido en medio alcalino que en medio ácido, lo que permite obtener formulaciones mejoradas de liberación pulsátil
UY0001032304A 2008-12-12 2009-12-07 Composición de liberación pulsátil de sildenafil y proceso para prepararla UY32304A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/003466 WO2010067140A1 (es) 2008-12-12 2008-12-12 Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Publications (1)

Publication Number Publication Date
UY32304A true UY32304A (es) 2010-05-31

Family

ID=42242382

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032304A UY32304A (es) 2008-12-12 2009-12-07 Composición de liberación pulsátil de sildenafil y proceso para prepararla

Country Status (13)

Country Link
US (1) US20110244050A1 (es)
EP (1) EP2374460A4 (es)
AR (1) AR071970A1 (es)
BR (1) BRPI0823356A2 (es)
CL (1) CL2009002173A1 (es)
CR (1) CR20110322A (es)
EC (1) ECSP11011194A (es)
MX (1) MX339136B (es)
NI (1) NI201100119A (es)
PA (1) PA8853801A1 (es)
PE (1) PE20100471A1 (es)
UY (1) UY32304A (es)
WO (1) WO2010067140A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018149B1 (pt) * 2012-01-27 2020-09-29 Siegfried Rhein S.A. De C.V Composição farmacêutica de nitazoxanida
EA019381B1 (ru) * 2012-07-20 2014-03-31 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Таблетка, содержащая ингибитор фосфодиэстеразы пятого типа, способ ее получения и ее применение
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
KR20000069899A (ko) 1997-01-06 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 속방성 및 미각 차폐성 약제학적 용량 형태
CA2235642C (en) 1998-05-15 2007-11-13 Torcan Chemical Ltd. Processes for preparing sildenafil
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
ES2953390T3 (es) * 2006-08-31 2023-11-10 Adare Pharmaceuticals Inc Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos

Also Published As

Publication number Publication date
WO2010067140A1 (es) 2010-06-17
CL2009002173A1 (es) 2010-04-09
MX2011005752A (es) 2011-08-12
MX339136B (es) 2016-05-13
CR20110322A (es) 2011-10-25
PA8853801A1 (es) 2010-07-27
AR071970A1 (es) 2010-07-28
EP2374460A1 (en) 2011-10-12
NI201100119A (es) 2012-08-03
BRPI0823356A2 (pt) 2015-06-16
ECSP11011194A (es) 2011-09-30
EP2374460A4 (en) 2013-08-21
US20110244050A1 (en) 2011-10-06
PE20100471A1 (es) 2010-07-22

Similar Documents

Publication Publication Date Title
NI201100119A (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla.
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
WO2008124617A3 (en) Rapidly dissolving pharmaceutical compositions comprising pullulan
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
TN2014000441A1 (en) A delayed release drug formulation
TW200744665A (en) Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
ES2526606T3 (es) Composición farmacéutica sólida que comprende amlodipina y losartán
CR10975A (es) Formulaciones para el tratamiento del cancer
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
AR067084A1 (es) Dispersion solida que contiene revaprazan y procedimiento para la preparacion de la misma. composicion farmaceutica.
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
MX2010005013A (es) Composiciones intranasales.
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
CU20090200A7 (es) Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
CO6630089A2 (es) Composicion de encapsulamiento de liberacion rapida
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
CO6390108A2 (es) Composición de liberación pulsatil de sildenafil y proceso para prepararla
DOP2011000181A (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210204